Psychotropic Medication Focus Group Recommendations

1) Studying psychotropic medication use in children/adolescents was difficult because the data were largely unavailable and very difficult to obtain - improvements in data access for stronger data analysis opportunities must be made. We need to be able to not only know how many individuals are receiving any particular medication of interest, but we should also be able to understand what combinations are being used as well as the total # of medications per child/adolescent. Lastly, we need to be able to understand who is prescribing the medications and if the patient has a single provider, or multiple providers.

2) Future efforts should look to use the attached AACAP document as a resource.

3) DCF’s Psychotropic Medication Advisory Committee should be the vehicle for all the medication tasks outlined in the Task Force’s mission, and that monetary and personnel support be granted to PMAC to assist in data collection and data analysis.